Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial
Jiang He,Nanxiang Ouyang,Xiaofan Guo,Guozhe Sun,Zhao Li,Jianjun Mu,Dao Wen Wang,Lixia Qiao,Liying Xing,Guocheng Ren,Chunxia Zhao,Ruihai Yang,Zuyi Yuan,Chang Wang,Chuning Shi,Songyue Liu,Wei Miao,Guangxiao Li,Chung-Shiuan Chen,Yingxian Sun,Xingang Zhang,Jun Wang,Ying Zhou,Ning Ye,Zihan Chen,Pengyu Zhang,Zihao Fan,Nan Ye,Linlin Zhang,Danxi Geng,Shu Zhang,Qiyu Li,Qiying Qin,Canru Liu,Xiaoyu Zheng,Tao Wang,Li Jing,Boqiang Zhang,Qun Sun,Yu Yan,Yueyuan Liao,Qiong Ma,Chao Chu,Yue Sun,Dan Wang,Ling Zhou,Heng Ye,Haoran Wei,Hao Liu,Zhaoqing Sun,Liqiang Zheng,Yanli Chen,Ye Chang,Mohan Jiang,Hongmei Yang,Shasha Yu,Wenna Li,Ning Wang,Chunwei Wu,Lufan Sun,Zhi Du,Yan Li,Nan Gao,Xinchi Liu,Ying Wang,Mingang Huang,Yufang Zhou,Lingrui Meng,Jiawen Zhang,Zhen Huang,Huihui Chen,Yuxian Huang,Lingmin Sun,Xin Zhong,Hanmin Wang,Xinyan Hou,Huan Han,Baohui Jin,Hua He
DOI: https://doi.org/10.1016/s0140-6736(22)02603-4
IF: 202.731
2023-03-04
The Lancet
Abstract:Summary Background Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention on cardiovascular disease has not been established. We aimed to test the effectiveness of such an intervention compared with usual care on risk of cardiovascular disease and all-cause death among individuals with hypertension. Methods In this open-label, blinded-endpoint, cluster-randomised trial, we recruited individuals aged at least 40 years with an untreated systolic blood pressure of at least 140 mm Hg or a diastolic blood pressure of at least 90 mm Hg (≥130 mm Hg and ≥80 mm Hg for those at high risk for cardiovascular disease or if currently taking antihypertensive medication). We randomly assigned (1:1) 326 villages to a non-physician community health-care provider-led intervention or usual care, stratified by provinces, counties, and townships. In the intervention group, trained non-physician community health-care providers initiated and titrated antihypertensive medications according to a simple stepped-care protocol to achieve a systolic blood pressure goal of less than 130 mm Hg and diastolic blood pressure goal of less than 80 mm Hg with supervision from primary care physicians. They also delivered discounted or free antihypertensive medications and health coaching for patients. The primary effectiveness outcome was a composite outcome of myocardial infarction, stroke, heart failure requiring hospitalisation, and cardiovascular disease death during the 36-month follow-up in the study participants. Safety was assessed every 6 months. This trial is registered with ClinicalTrials.gov , NCT03527719 . Findings Between May 8 and Nov 28, 2018, we enrolled 163 villages per group with 33 995 participants. Over 36 months, the net group difference in systolic blood pressure reduction was –23·1 mm Hg (95% CI –24·4 to –21·9; p<0·0001) and in diastolic blood pressure reduction, it was –9·9 mm Hg (–10·6 to –9·3; p<0·0001). Fewer patients in the intervention group than the usual care group had a primary outcome (1·62% vs 2·40% per year; hazard ratio [HR] 0·67, 95% CI 0·61–0·73; p<0·0001). Secondary outcomes were also reduced in the intervention group: myocardial infarction (HR 0·77, 95% CI 0·60–0·98; p=0·037), stroke (0·66, 0·60–0·73; p<0·0001), heart failure (0·58, 0·42–0·81; p=0·0016), cardiovascular disease death (0·70, 0·58–0·83; p<0·0001), and all-cause death (0·85, 0·76–0·95; p=0·0037). The risk reduction of the primary outcome was consistent across subgroups of age, sex, education, antihypertensive medication use, and baseline cardiovascular disease risk. Hypotension was higher in the intervention than in the usual care group (1·75% vs 0·89%; p<0·0001). Interpretation The non-physician community health-care provider-led intensive blood pressure intervention is effective in reducing cardiovascular disease and death. Funding The Ministry of Science and Technology of China and the Science and Technology Program of Liaoning Province, China.
medicine, general & internal